

Recent developments in the medical and surgical treatment

Ca-A Cancer Journal for Clinicians

64, 171-185

DOI: [10.3322/caac.21224](https://doi.org/10.3322/caac.21224)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Immunotherapy of melanoma: Present options and future promises. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 115-128.	2.7	59
2	Tapping the Potential of DNA Delivery with Electroporation for Cancer Immunotherapy. <i>Current Topics in Microbiology and Immunology</i> , 2015, 405, 55-78.	0.7	10
3	Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanoma. <i>Melanoma Management</i> , 2015, 2, 133-147.	0.1	3
4	Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant. , 2015, 3, 10.		11
5	Hierarchical coated metal hydroxide nanoconstructs as potential controlled release carriers of photosensitizer for skin melanoma. <i>RSC Advances</i> , 2015, 5, 42666-42680.	1.7	33
6	Oncolytic Virus Immunotherapy for Melanoma. <i>Current Treatment Options in Oncology</i> , 2015, 16, 326.	1.3	40
7	The sentinel node procedure in early stage cervical cancer, taking the next step; a diagnostic review. <i>Gynecologic Oncology</i> , 2015, 139, 559-567.	0.6	103
8	Nivolumab: A Review in Advanced Melanoma. <i>Drugs</i> , 2015, 75, 1413-1424.	4.9	44
9	The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials. <i>OncoTargets and Therapy</i> , 2016, 9, 1571.	1.0	7
10	Evolving systemic targeted therapy strategies in uveal melanoma and implications for ophthalmic management: a review. <i>Clinical and Experimental Ophthalmology</i> , 2016, 44, 509-519.	1.3	18
11	Malignant Melanoma: Beyond the Basics. <i>Plastic and Reconstructive Surgery</i> , 2016, 138, 330e-340e.	0.7	121
12	Epidemiology of cutaneous melanoma in Sweden—Stage-specific survival and rate of recurrence. <i>International Journal of Cancer</i> , 2016, 139, 2722-2729.	2.3	49
13	MiR-330-5p regulates tyrosinase and PDIA3 expression and suppresses cell proliferation and invasion in cutaneous malignant melanoma. <i>Journal of Surgical Research</i> , 2016, 203, 434-440.	0.8	36
14	Synthesis and biological evaluation of thiophene and benzo[b]thiophene analogs of combretastatin A-4 and isocombretastatin A-4: A comparison between the linkage positions of the 3,4,5-trimethoxystyrene unit. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 174-180.	1.0	22
15	In vitro and in vivo efficacy and safety evaluation of metapristone and mifepristone as cancer metastatic chemopreventive agents. <i>Biomedicine and Pharmacotherapy</i> , 2016, 78, 291-300.	2.5	19
16	Inhibition of tyrosinase by 4 H-chromene analogs: Synthesis, kinetic studies, and computational analysis. <i>Chemical Biology and Drug Design</i> , 2017, 90, 804-810.	1.5	15
18	Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 469-473.	1.5	9
19	Vitexin compound 1, a novel extraction from a Chinese herb, suppresses melanoma cell growth through DNA damage by increasing ROS levels. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 269.	3.5	53

#	ARTICLE	IF	CITATIONS
20	Impact of rurality on processes and outcomes in melanoma care: results from a whole-Scotland melanoma cohort in primary and secondary care. <i>British Journal of General Practice</i> , 2018, 68, e566-e575.	0.7	10
21	Clinicopathological presentations and surgical outcomes of esophageal melanoma. <i>Asian Cardiovascular and Thoracic Annals</i> , 2019, 27, 548-553.	0.2	2
22	Long noncoding RNA CPS1 ^{lnc} suppresses melanoma cell metastasis through inhibiting Cyr61 via competitively binding to BRG1. <i>Journal of Cellular Physiology</i> , 2019, 234, 22017-22027.	2.0	20
23	IL-33/ST2 Axis Regulates Vasculogenic Mimicry via ERK1/2-MMP-2/9 Pathway in Melanoma. <i>Dermatology</i> , 2019, 235, 225-233.	0.9	21
24	Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations. <i>Clinical Cancer Research</i> , 2019, 25, 3548-3560.	3.2	74
25	Suppression of PMA-induced human fibrosarcoma HT-1080 invasion and metastasis by kahweol via inhibiting Akt/JNK1/2/p38 MAPK signal pathway and NF- κ B dependent transcriptional activities. <i>Food and Chemical Toxicology</i> , 2019, 125, 1-9.	1.8	15
26	Efficacy and safety of dabrafenib ⁺ trametinib in the treatment of unresectable advanced/metastatic melanoma with BRAF ^{V600} mutation: A systematic review and network meta-analysis. <i>Dermatologic Therapy</i> , 2020, 33, e13145.	0.8	8
27	Efficacy and safety of dabrafenib ⁺ trametinib in the treatment of unresectable or metastatic melanoma with BRAF V600 mutation: A systematic review and network meta-analysis. <i>Dermatologic Therapy</i> , 2020, 33, e14135.	0.8	1
28	Circ-GLI1 promotes metastasis in melanoma through interacting with p70S6K2 to activate Hedgehog/GLI1 and Wnt/ β -catenin pathways and upregulate Cyr61. <i>Cell Death and Disease</i> , 2020, 11, 596.	2.7	33
29	Functional Roles of Matrix Metalloproteinases and Their Inhibitors in Melanoma. <i>Cells</i> , 2020, 9, 1151.	1.8	78
30	Chondroitin polymerizing factor (CHPF) promotes development of malignant melanoma through regulation of CDK1. <i>Cell Death and Disease</i> , 2020, 11, 496.	2.7	18
31	Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma. <i>JCO Precision Oncology</i> , 2020, 4, 319-334.	1.5	67
32	Melanoma Detection Using Spatial and Spectral Analysis on Superpixel Graphs. <i>Journal of Digital Imaging</i> , 2021, 34, 162-181.	1.6	11
33	Giant congenital nodular melanoma in a newborn: a case report and literature review. <i>BMC Pediatrics</i> , 2021, 21, 121.	0.7	1
34	Developments in therapy for brain metastases in melanoma patients. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1443-1453.	0.9	1
35	Evaluation of the reporting quality of clinical practice guidelines on melanoma using the RIGHT checklist. <i>Annals of Translational Medicine</i> , 2021, 9, 1172-1172.	0.7	0
36	Nanodelivery of a self-assembling prodrug with exceptionally high drug loading potentiates chemotherapy efficacy. <i>International Journal of Pharmaceutics</i> , 2021, 605, 120805.	2.6	6
37	Non-coding RNAs in melanoma: Biological functions and potential clinical applications. <i>Molecular Therapy - Oncolytics</i> , 2021, 22, 219-231.	2.0	11

#	ARTICLE	IF	CITATIONS
38	The regulation of NONO by USP11 via deubiquitination is linked to the proliferation of melanoma cells. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 1507-1517.	1.6	13
39	PCTAIRE1 regulates p27 stability, apoptosis and tumor growth in malignant melanoma. <i>Oncoscience</i> , 2014, 1, 624-633.	0.9	20
40	MicroRNA-610 inhibits tumor growth of melanoma by targeting LRP6. <i>Oncotarget</i> , 2017, 8, 97361-97370.	0.8	10
41	Bioactive Albumin-Based Carriers for Tumour Chemotherapy. <i>Current Cancer Drug Targets</i> , 2014, 14, 752-763.	0.8	14
42	MiR-186 inhibits cell proliferation and invasion in human cutaneous malignant melanoma. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, S60-S64.	0.3	12
43	Cost-Effectiveness of the Dabrafenib Schedule in Combination With Trametinib Compared With Other Targeted Therapies, Immunotherapy, and Dacarbazine for the Treatment of Unresectable or Metastatic Melanoma With BRAFV600 Mutation in Colombia. <i>Value in Health Regional Issues</i> , 2021, 26, 182-190.	0.5	2
44	Managing Advanced Melanoma: Targeting the PD-1 Pathway with Pembrolizumab. <i>Cancer Research Frontiers</i> , 2015, 1, 127-137.	0.2	0
45	Clinical characteristics of malignant melanoma in central China and predictors of metastasis. <i>Oncology Letters</i> , 2020, 19, 1452-1464.	0.8	5
46	The new horizon of biomarker in melanoma patients. <i>Medicine (United States)</i> , 2022, 101, e28553.	0.4	7
47	Immune-related lncRNA pairs as novel signature to predict prognosis and immune landscape in melanoma patients. <i>Medicine (United States)</i> , 2022, 101, e28531.	0.4	2
48	Immune Landscape and an RBM38-Associated Immune Prognostic Model with Laboratory Verification in Malignant Melanoma. <i>Cancers</i> , 2022, 14, 1590.	1.7	2
49	Comprehensive analysis of the expression and prognosis for GPXs in cutaneous melanoma using bioinformatics analysis. <i>Biomedical Signal Processing and Control</i> , 2022, 77, 103804.	3.5	0
51	Treated Dentin Matrix in Tissue Regeneration: Recent Advances. <i>Pharmaceutics</i> , 2023, 15, 91.	2.0	2
52	Long-term outcomes of margin-controlled excision for eyelid melanoma. <i>Eye</i> , 2023, 37, 1009-1013.	1.1	1
53	A feasibility study comparing car-t cell therapy and separate limb end perfusion therapy in the treatment of melanoma. , 0, 36, 1-7.		0
54	Comparison of Prognostic Factors for Merkel Cell Carcinoma, Mucosal Melanoma and Cutaneous Malignant Melanoma: Insights into Their Etiologies. <i>Current Oncology</i> , 2023, 30, 3974-3988.	0.9	2